Experimental drug improves survival in certain AML patients | Dana-Farber Cancer Institute
1,903 views · Published 6 December 2015 · 2:06 · Indexed 30 October 2026
Channel: Dana-Farber Cancer Institute · 2015 · Science & Technology
Dana-Farber scientists report at the 57th American Society of Hematology (ASH) Annual Meeting that midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia.
More from this channel
-
0:18
Importance of Joining the Stem Cell Registry | Dana-Farber Cancer Institute
-
0:20
How to Join the Stem Cell Registry | Dana-Farber Cancer Institute
-
0:18
How to Register as a Stem Cell Donor | Dana-Farber Cancer Institute
-
3:03
Sportscaster Jim Britt for the Jimmy Fund | Dana-Farber Cancer Institute
-
0:07
Dana-Farber Banners | Dana-Farber Cancer Institute
-
2:08
Barbers for the Jimmy Fund | Dana-Farber Cancer Institute
-
1:43
Pets | Dana-Farber Cancer Institute
-
1:34
Healthy Eating for the Holiday Season | Dana-Farber Cancer Institute